In one paragraphArticle in International cancer conference journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
16 authors.
Takehiro NakaoDepartment of Medical Oncology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-Ku, Tokyo, 135-8550 Japan.ORCID 0009-0008-4421-0997 Naoki FukudaDepartment of Medical Oncology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-Ku, Tokyo, 135-8550 Japan.ORCID 0000-0002-5475-9309 Xiaofei WangDepartment of Medical Oncology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-Ku, Tokyo, 135-8550 Japan.ORCID 0000-0002-1471-4560 Ryosuke OkiDepartment of Medical Oncology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-Ku, Tokyo, 135-8550 Japan.
Tetsuya UrasakiDepartment of Medical Oncology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-Ku, Tokyo, 135-8550 Japan.
Kenji NakanoDepartment of Medical Oncology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-Ku, Tokyo, 135-8550 Japan.ORCID 0000-0002-3721-004X Makiko OnoDepartment of Medical Oncology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-Ku, Tokyo, 135-8550 Japan.
Junichi TomomatsuDepartment of Medical Oncology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-Ku, Tokyo, 135-8550 Japan.ORCID 0000-0002-2130-5183 Ryo AriyasuDepartment of Thoracic Medical Oncology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan.
Yukiko SatoDivison of Pathology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan.ORCID 0000-0003-4277-0161 Ippei FukadaDepartment of Genomic Medicine, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan.
Toru SasakiDivision of Head and Neck, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan.ORCID 0000-0002-2924-3255 Kengo TakeuchiDivison of Pathology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan.ORCID 0000-0002-1599-5800 Makoto NishioDepartment of Thoracic Medical Oncology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan.
Yuji MiuraDepartment of Medical Oncology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-Ku, Tokyo, 135-8550 Japan.ORCID 0000-0002-7091-628X Shunji TakahashiDepartment of Medical Oncology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-Ku, Tokyo, 135-8550 Japan.ORCID 0000-0002-5031-1953 Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
Soft-tissue sarcoma (STS) is a rare malignancy that accounts for less than 1% of all cancers, and recent advances in molecular biology have led to its classification based on genomic information. Some
Indexed as
Next-generation sequencingRET fusionSelpercatinibSoft-tissue sarcomasTargeted therapy
Identifiers
PMID41395549
PMCPMC12696271
What OpenQuestion holds
Textmetadata
Read underepoch 390